NOVELTY - Preparation of fluvoxamine maleate (I), involves condensing 5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one (II), with hydroxylamine hydrochloride in presence of sodium carbonate granules in solvent, isolating and treating obtained 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine (III), with 2-chloroethylamine hydrochloride, extracting obtained (E)-(2-aminoethoxy)((5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene))amine (IV) with solvent, treating the obtained organic layer with maleic acid, isolating and purifying the crude fluvoxamine maleate (I).    USE - Preparation of fluvoxamine maleate used for treating depressive disorder, obsessive-compulsive disorder, and anxiety disorders such as post-traumatic stress disorder.    ADVANTAGE - The method enables easy, economical, environmentally-friendly and efficient preparation of fluvoxamine maleate having high purity with high yield.    DETAILED DESCRIPTION - Preparation of fluvoxamine maleate of formula (I), involves condensing 5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one of formula (II), with hydroxylamine hydrochloride in the presence of sodium carbonate granules in solvent to form 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine of formula (III), isolating 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine of formula (III), treating 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine of formula (III) with 2-chloroethylamine hydrochloride, in the presence of base in solvent at 40-45 degrees C to form (E)-(2-aminoethoxy)((5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene))amine of formula (IV), extracting (E)-(2-aminoethoxy)((5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene))amine of formula (IV) with solvent to form an organic layer, treating the obtained organic layer with maleic acid, isolating crude fluvoxamine maleate of formula (I) and optionally purifying fluvoxamine maleate of formula (I). INDEPENDENT CLAIMS are included for the following:    (1) preparation of 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine of formula (III), which involves treating 5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one of formula (II) with hydroxylamine hydrochloride, in the presence of sodium carbonate granules in solvent at 45-50 degrees C; and    (2) isolation of 5-methoxy-l-(4-(trifluoromethyl)phenyl)pentan-1-one of formula (II) from mixture of (IE)+(IZ) of 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-imine of formula (III), which involves treating 1-N-hydroxy-5-methoxy-1-(4-(trifluoromethyl) phenyl)pentan-1-imine of formula (III) with aqueous hydrochloric acid.